{'fraction_non_alphanumeric': 0.022916666666666665, 'fraction_numerical': 0.0020833333333333333, 'mean_word_length': 4.795180722891566, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunosuppression, Generic Drugs and the FDA

In this issue, Dr. Momper and his co-investigators from the University of Pittsburgh report a study of converting liver and kidney transplant recipients from brand name to generic tacrolimus (1). The paper is important, as it is the first formal study after such conversion. The reason to convert patients to a generic substitute is obvious: we are trying to lower the cost of immunosuppression for our patients and for the community.